Boehringer Ingelheim has begun an expansion of Oasis, its Shanghai biologic contract manufacturing facility, including an additional bioreactor and sufficient infrastructure to support the GMP operations of 2x2000L single use bioreactor manufacturing lines. BI explained that one of its contracted mAbs is close to commercial production, with several additional candidates in its pipeline expected to follow soon. It did not identify the products.
Source: China Biotoday
